| pubmed-article:9455808 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9455808 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:9455808 | lifeskim:mentions | umls-concept:C0003324 | lld:lifeskim |
| pubmed-article:9455808 | lifeskim:mentions | umls-concept:C0030956 | lld:lifeskim |
| pubmed-article:9455808 | lifeskim:mentions | umls-concept:C1334510 | lld:lifeskim |
| pubmed-article:9455808 | lifeskim:mentions | umls-concept:C0385723 | lld:lifeskim |
| pubmed-article:9455808 | lifeskim:mentions | umls-concept:C0004083 | lld:lifeskim |
| pubmed-article:9455808 | lifeskim:mentions | umls-concept:C0439859 | lld:lifeskim |
| pubmed-article:9455808 | lifeskim:mentions | umls-concept:C1159929 | lld:lifeskim |
| pubmed-article:9455808 | lifeskim:mentions | umls-concept:C0086414 | lld:lifeskim |
| pubmed-article:9455808 | lifeskim:mentions | umls-concept:C0173677 | lld:lifeskim |
| pubmed-article:9455808 | lifeskim:mentions | umls-concept:C0185027 | lld:lifeskim |
| pubmed-article:9455808 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:9455808 | pubmed:dateCreated | 1998-2-20 | lld:pubmed |
| pubmed-article:9455808 | pubmed:abstractText | From the peripheral blood lymphocytes (PBLs) of melanoma patient SK29(AV) we have previously isolated 2 independent cytolytic T lymphocyte (CTL) clones (CTL7/147 and CTL13/211), which lysed autologous tumor cells in association with HLA-B45.1. As demonstrated here, both CTL clones were directed against melanocyte differentiation antigen Melan-A/MART-1, which also was recognized by HLA-A2.1-restricted CTLs from the same patient. By generating and transfecting 3'-deletion mutants of Melan-A/MART-1 cDNA, we localized its peptide-coding regions. The HLA-B45.1-presented peptides were derived from a hydrophobic region of the protein and largely overlapped the peptides recognized by CTLs from the same patient in association with HLA-A2.1. We determined the fine specificity of these CTL clones with synthetic peptides. CTL clone CTL7/147 recognized the 11-mer peptide AEEAAGIGILT (residues 24-34) at the lowest concentrations. The absence of threonine-34 abrogated the recognition by CTL7/147. The truncated peptide AEEAAGIGIL (residues 24-33) proved to be the optimal synthetic peptide for sensitization against lysis by CTL13/211. This indicated that C-terminal threonine-34 was not involved in binding to HLA-B45.1 but, rather, was part of the epitope for CTL7/147. HLA-B45.1-associated peptides of Melan-A/MART-1 were regularly processed and presented by other melanomas and other cell types. Three of 4 independent HLA-A2.1-restricted SK29-CTL clones recognized the 10-mer peptide EAAGIGILTV (residues 26-35) at 10- to 100-fold lower concentrations than the nonamer AAGIGILTV (residues 27-35), previously described as the common immunodominant peptide antigen for all known anti-Melan-A/MART-1 CTLs restricted by HLA-A2.1. Different melanoma peptide antigens currently are applied in therapeutic vaccination studies. Our findings emphasize that restricting to peptides of minimal length might exclude relevant T-cell epitopes. | lld:pubmed |
| pubmed-article:9455808 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9455808 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9455808 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9455808 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9455808 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9455808 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9455808 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9455808 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9455808 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9455808 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9455808 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9455808 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9455808 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9455808 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:9455808 | pubmed:issn | 0020-7136 | lld:pubmed |
| pubmed-article:9455808 | pubmed:author | pubmed-author:SchneiderJJ | lld:pubmed |
| pubmed-article:9455808 | pubmed:author | pubmed-author:Meyer zum... | lld:pubmed |
| pubmed-article:9455808 | pubmed:author | pubmed-author:BoonTT | lld:pubmed |
| pubmed-article:9455808 | pubmed:author | pubmed-author:WölfelTT | lld:pubmed |
| pubmed-article:9455808 | pubmed:author | pubmed-author:BrichardVV | lld:pubmed |
| pubmed-article:9455808 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9455808 | pubmed:day | 30 | lld:pubmed |
| pubmed-article:9455808 | pubmed:volume | 75 | lld:pubmed |
| pubmed-article:9455808 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9455808 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9455808 | pubmed:pagination | 451-8 | lld:pubmed |
| pubmed-article:9455808 | pubmed:dateRevised | 2011-5-23 | lld:pubmed |
| pubmed-article:9455808 | pubmed:meshHeading | pubmed-meshheading:9455808-... | lld:pubmed |
| pubmed-article:9455808 | pubmed:meshHeading | pubmed-meshheading:9455808-... | lld:pubmed |
| pubmed-article:9455808 | pubmed:meshHeading | pubmed-meshheading:9455808-... | lld:pubmed |
| pubmed-article:9455808 | pubmed:meshHeading | pubmed-meshheading:9455808-... | lld:pubmed |
| pubmed-article:9455808 | pubmed:meshHeading | pubmed-meshheading:9455808-... | lld:pubmed |
| pubmed-article:9455808 | pubmed:meshHeading | pubmed-meshheading:9455808-... | lld:pubmed |
| pubmed-article:9455808 | pubmed:meshHeading | pubmed-meshheading:9455808-... | lld:pubmed |
| pubmed-article:9455808 | pubmed:meshHeading | pubmed-meshheading:9455808-... | lld:pubmed |
| pubmed-article:9455808 | pubmed:meshHeading | pubmed-meshheading:9455808-... | lld:pubmed |
| pubmed-article:9455808 | pubmed:meshHeading | pubmed-meshheading:9455808-... | lld:pubmed |
| pubmed-article:9455808 | pubmed:meshHeading | pubmed-meshheading:9455808-... | lld:pubmed |
| pubmed-article:9455808 | pubmed:meshHeading | pubmed-meshheading:9455808-... | lld:pubmed |
| pubmed-article:9455808 | pubmed:meshHeading | pubmed-meshheading:9455808-... | lld:pubmed |
| pubmed-article:9455808 | pubmed:meshHeading | pubmed-meshheading:9455808-... | lld:pubmed |
| pubmed-article:9455808 | pubmed:meshHeading | pubmed-meshheading:9455808-... | lld:pubmed |
| pubmed-article:9455808 | pubmed:meshHeading | pubmed-meshheading:9455808-... | lld:pubmed |
| pubmed-article:9455808 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9455808 | pubmed:articleTitle | Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1. | lld:pubmed |
| pubmed-article:9455808 | pubmed:affiliation | I Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität, Mainz, Germany. | lld:pubmed |
| pubmed-article:9455808 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9455808 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9455808 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9455808 | lld:pubmed |
